Determinant Factors Associated with Occurrence of Tuberculosis among Adult People Living with HIV after Antiretroviral Treatment Initiation in Addis Ababa, Ethiopia: A Case Control Study
Identifieur interne : 002A34 ( Pmc/Corpus ); précédent : 002A33; suivant : 002A35Determinant Factors Associated with Occurrence of Tuberculosis among Adult People Living with HIV after Antiretroviral Treatment Initiation in Addis Ababa, Ethiopia: A Case Control Study
Auteurs : Kelemu Tilahun Kibret ; Alemayehu Worku Yalew ; Belaineh Girma Belaineh ; Muluken Melese AsresSource :
- PLoS ONE [ 1932-6203 ] ; 2013.
Abstract
Tuberculosis (TB) is a leading morbidity and mortality, and the first presenting sign in majority of people living with Human Immune deficiency Virus (PLWH). Determinants of active TB among HIV patients on anti retroviral treatment (ART) are not well described in resource limited settings. The aim of this study was to assess determinant factors for the occurrence of TB among people living with HIV after ART initiation in public hospitals and health centers in Addis Ababa, Ethiopia.
A case control study was conducted from December 2011 to February 2012 in 2 public hospitals and 13 health centers in Addis Ababa. The study population consisted of 204 cases and 409 controls. Cases were adult people living with HIV who developed TB after ART initiation and controls were adult people living with HIV who did not develop TB after ART initiation. An interviewer administered structured questionnaire was used to collect information.
After adjustment for potential confounders, presence of isoniazid prophylaxis (adjusted odd ratio [AOR] 0.35, 95% confidence interval [CI] 0.125, 0.69) and cotrimoxazole prophylaxis (AOR = 0.19; 95% CI: 0.06, 0.62) had protective benefit against risk of TB. In contrary, bedridden (AOR = 9.36; 95% CI: 3.39, 25.85), having World Health Organization (WHO) clinical stage III/IV (AOR = 3.40; 95% CI: 1.69, 6.87) and hemoglobin level <10 mg/dl (AOR = 7.43; 95% CI; 3.04, 18.31) at enrollment to ART care were predictors for increased risk of tuberculosis in PLWH after ART initiation.
Increasing coverage of isoniazid preventive therapy and cotrimoxazole preventive therapy reduced risk of TB among HIV patients who started treatment. All PLWH should be screened for TB, but for patients who have advanced disease condition (WHO clinical stage III/IV, being bedridden and having hemoglobin level <10 mg/dl) intensified screening is highly recommended during treatment follow up.
Url:
DOI: 10.1371/journal.pone.0064488
PubMed: 23762214
PubMed Central: 3660598
Links to Exploration step
PMC:3660598Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Determinant Factors Associated with Occurrence of Tuberculosis among Adult People Living with HIV after Antiretroviral Treatment Initiation in Addis Ababa, Ethiopia: A Case Control Study</title><author><name sortKey="Kibret, Kelemu Tilahun" sort="Kibret, Kelemu Tilahun" uniqKey="Kibret K" first="Kelemu Tilahun" last="Kibret">Kelemu Tilahun Kibret</name><affiliation><nlm:aff id="aff1"><addr-line>Department of Public Health, College of Medical and Health Science, Wollega University, Nekemte, Ethiopia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Yalew, Alemayehu Worku" sort="Yalew, Alemayehu Worku" uniqKey="Yalew A" first="Alemayehu Worku" last="Yalew">Alemayehu Worku Yalew</name><affiliation><nlm:aff id="aff2"><addr-line>School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Belaineh, Belaineh Girma" sort="Belaineh, Belaineh Girma" uniqKey="Belaineh B" first="Belaineh Girma" last="Belaineh">Belaineh Girma Belaineh</name><affiliation><nlm:aff id="aff3"><addr-line>Help Ethiopia Address Low TB Performance (HEAL TB) Project, USAID/Management Sciences for Health (MSH), Addis Ababa, Ethiopia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Asres, Muluken Melese" sort="Asres, Muluken Melese" uniqKey="Asres M" first="Muluken Melese" last="Asres">Muluken Melese Asres</name><affiliation><nlm:aff id="aff3"><addr-line>Help Ethiopia Address Low TB Performance (HEAL TB) Project, USAID/Management Sciences for Health (MSH), Addis Ababa, Ethiopia</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23762214</idno><idno type="pmc">3660598</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660598</idno><idno type="RBID">PMC:3660598</idno><idno type="doi">10.1371/journal.pone.0064488</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">002A34</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002A34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Determinant Factors Associated with Occurrence of Tuberculosis among Adult People Living with HIV after Antiretroviral Treatment Initiation in Addis Ababa, Ethiopia: A Case Control Study</title><author><name sortKey="Kibret, Kelemu Tilahun" sort="Kibret, Kelemu Tilahun" uniqKey="Kibret K" first="Kelemu Tilahun" last="Kibret">Kelemu Tilahun Kibret</name><affiliation><nlm:aff id="aff1"><addr-line>Department of Public Health, College of Medical and Health Science, Wollega University, Nekemte, Ethiopia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Yalew, Alemayehu Worku" sort="Yalew, Alemayehu Worku" uniqKey="Yalew A" first="Alemayehu Worku" last="Yalew">Alemayehu Worku Yalew</name><affiliation><nlm:aff id="aff2"><addr-line>School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Belaineh, Belaineh Girma" sort="Belaineh, Belaineh Girma" uniqKey="Belaineh B" first="Belaineh Girma" last="Belaineh">Belaineh Girma Belaineh</name><affiliation><nlm:aff id="aff3"><addr-line>Help Ethiopia Address Low TB Performance (HEAL TB) Project, USAID/Management Sciences for Health (MSH), Addis Ababa, Ethiopia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Asres, Muluken Melese" sort="Asres, Muluken Melese" uniqKey="Asres M" first="Muluken Melese" last="Asres">Muluken Melese Asres</name><affiliation><nlm:aff id="aff3"><addr-line>Help Ethiopia Address Low TB Performance (HEAL TB) Project, USAID/Management Sciences for Health (MSH), Addis Ababa, Ethiopia</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Introduction</title><p>Tuberculosis (TB) is a leading morbidity and mortality, and the first presenting sign in majority of people living with Human Immune deficiency Virus (PLWH). Determinants of active TB among HIV patients on anti retroviral treatment (ART) are not well described in resource limited settings. The aim of this study was to assess determinant factors for the occurrence of TB among people living with HIV after ART initiation in public hospitals and health centers in Addis Ababa, Ethiopia.</p></sec><sec><title>Methods and Findings</title><p>A case control study was conducted from December 2011 to February 2012 in 2 public hospitals and 13 health centers in Addis Ababa. The study population consisted of 204 cases and 409 controls. Cases were adult people living with HIV who developed TB after ART initiation and controls were adult people living with HIV who did not develop TB after ART initiation. An interviewer administered structured questionnaire was used to collect information.</p><p>After adjustment for potential confounders, presence of isoniazid prophylaxis (adjusted odd ratio [AOR] 0.35, 95% confidence interval [CI] 0.125, 0.69) and cotrimoxazole prophylaxis (AOR = 0.19; 95% CI: 0.06, 0.62) had protective benefit against risk of TB. In contrary, bedridden (AOR = 9.36; 95% CI: 3.39, 25.85), having World Health Organization (WHO) clinical stage III/IV (AOR = 3.40; 95% CI: 1.69, 6.87) and hemoglobin level <10 mg/dl (AOR = 7.43; 95% CI; 3.04, 18.31) at enrollment to ART care were predictors for increased risk of tuberculosis in PLWH after ART initiation.</p></sec><sec><title>Conclusion</title><p>Increasing coverage of isoniazid preventive therapy and cotrimoxazole preventive therapy reduced risk of TB among HIV patients who started treatment. All PLWH should be screened for TB, but for patients who have advanced disease condition (WHO clinical stage III/IV, being bedridden and having hemoglobin level <10 mg/dl) intensified screening is highly recommended during treatment follow up.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Habib, Ag" uniqKey="Habib A">AG Habib</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bonnet, Mmb" uniqKey="Bonnet M">MMB Bonnet</name></author><author><name sortKey="Loretexu, Lpp" uniqKey="Loretexu L">LPP Loretexu</name></author><author><name sortKey="Francis, Fvv" uniqKey="Francis F">FVV Francis</name></author><author><name sortKey="Barbara, Boo" uniqKey="Barbara B">BOO Barbara</name></author><author><name sortKey="Daniel, Doo B" uniqKey="Daniel D">DOO'B Daniel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huruy, K" uniqKey="Huruy K">K Huruy</name></author><author><name sortKey="Mulu, A" uniqKey="Mulu A">A Mulu</name></author><author><name sortKey="Mengstu, G" uniqKey="Mengstu G">G Mengstu</name></author><author><name sortKey="Shewa, A" uniqKey="Shewa A">A Shewa</name></author><author><name sortKey="Akalu, A" uniqKey="Akalu A">A Akalu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lawn, Sd" uniqKey="Lawn S">SD Lawn</name></author><author><name sortKey="Badri, M" uniqKey="Badri M">M Badri</name></author><author><name sortKey="Wood, R" uniqKey="Wood R">R Wood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joshua, B" uniqKey="Joshua B">B Joshua</name></author><author><name sortKey="Mayanja Kizza, H" uniqKey="Mayanja Kizza H">H Mayanja-Kizza</name></author><author><name sortKey="Moses, Rk" uniqKey="Moses R">RK Moses</name></author><author><name sortKey="John, L" uniqKey="John L">L John</name></author><author><name sortKey="Andrew, K" uniqKey="Andrew K">K Andrew</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boccia, D" uniqKey="Boccia D">D Boccia</name></author><author><name sortKey="James, H" uniqKey="James H">H James</name></author><author><name sortKey="Bianca, Lds" uniqKey="Bianca L">LDS Bianca</name></author><author><name sortKey="Katherine, F" uniqKey="Katherine F">F Katherine</name></author><author><name sortKey="Chaap, Abs" uniqKey="Chaap A">AbS Chaap</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joshua, Baalwa" uniqKey="Joshua B">Baalwa Joshua</name></author><author><name sortKey="Mayanja Kizza, H" uniqKey="Mayanja Kizza H">H Mayanja-Kizza</name></author><author><name sortKey="Kamya, Mr" uniqKey="Kamya M">MR Kamya</name></author><author><name sortKey="John, L" uniqKey="John L">L John</name></author><author><name sortKey="Kambugu, A" uniqKey="Kambugu A">A Kambugu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taha, M" uniqKey="Taha M">M Taha</name></author><author><name sortKey="Derbew, A" uniqKey="Derbew A">A Derbew</name></author><author><name sortKey="Tessema, F" uniqKey="Tessema F">F Tessema</name></author><author><name sortKey="Assegid, S" uniqKey="Assegid S">S Assegid</name></author><author><name sortKey="Duchateau, L" uniqKey="Duchateau L">L Duchateau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lienhardt, C" uniqKey="Lienhardt C">C Lienhardt</name></author><author><name sortKey="Fielding, K" uniqKey="Fielding K">K Fielding</name></author><author><name sortKey="Sillah, Js" uniqKey="Sillah J">JS Sillah</name></author><author><name sortKey="Bah, B" uniqKey="Bah B">B Bah</name></author><author><name sortKey="Gustafson, P" uniqKey="Gustafson P">P Gustafson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hill Philip, C" uniqKey="Hill Philip C">C Hill Philip</name></author><author><name sortKey="Jackson Sillah, D" uniqKey="Jackson Sillah D">D Jackson-Sillah</name></author><author><name sortKey="Donkor, Sa" uniqKey="Donkor S">SA Donkor</name></author><author><name sortKey="Out, J" uniqKey="Out J">J Out</name></author><author><name sortKey="Adegbola, Ra" uniqKey="Adegbola R">RA Adegbola</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hermans, Sm" uniqKey="Hermans S">SM Hermans</name></author><author><name sortKey="Kiragga, A" uniqKey="Kiragga A">A Kiragga</name></author><author><name sortKey="Schaefer, P" uniqKey="Schaefer P">P Schaefer</name></author><author><name sortKey="Kambugu, A" uniqKey="Kambugu A">A Kambugu</name></author><author><name sortKey="Hoepelman, Aim" uniqKey="Hoepelman A">AIM Hoepelman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rodwell, L" uniqKey="Rodwell L">L Rodwell</name></author><author><name sortKey="Richard, Fwb" uniqKey="Richard F">FWB Richard</name></author><author><name sortKey="Moore, M" uniqKey="Moore M">M Moore</name></author><author><name sortKey="Strathdee, Sa" uniqKey="Strathdee S">SA Strathdee</name></author><author><name sortKey="Raich, A" uniqKey="Raich A">A Raich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lonnroth, K" uniqKey="Lonnroth K">K Lönnroth</name></author><author><name sortKey="Williams, Bg" uniqKey="Williams B">BG Williams</name></author><author><name sortKey="Stadlin, S" uniqKey="Stadlin S">S Stadlin</name></author><author><name sortKey="Jaramillo, E" uniqKey="Jaramillo E">E Jaramillo</name></author><author><name sortKey="Dye, C" uniqKey="Dye C">C Dye</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rehm, J" uniqKey="Rehm J">J Rehm</name></author><author><name sortKey="Samokhvalov, Av" uniqKey="Samokhvalov A">AV Samokhvalov</name></author><author><name sortKey="Neuman, Mg" uniqKey="Neuman M">MG Neuman</name></author><author><name sortKey="Room, R" uniqKey="Room R">R Room</name></author><author><name sortKey="Parry, C" uniqKey="Parry C">C Parry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Komati, S" uniqKey="Komati S">S Komati</name></author><author><name sortKey="Shaw, Pa" uniqKey="Shaw P">PA Shaw</name></author><author><name sortKey="Stubbs, N" uniqKey="Stubbs N">N Stubbs</name></author><author><name sortKey="Mathibedi, Mj" uniqKey="Mathibedi M">MJ Mathibedi</name></author><author><name sortKey="Malan, L" uniqKey="Malan L">L Malan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akolo, C" uniqKey="Akolo C">C Akolo</name></author><author><name sortKey="Adetifa, I" uniqKey="Adetifa I">I Adetifa</name></author><author><name sortKey="Shepperd, S" uniqKey="Shepperd S">S Shepperd</name></author><author><name sortKey="Volmink, J" uniqKey="Volmink J">J Volmink</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Golub, Je" uniqKey="Golub J">JE Golub</name></author><author><name sortKey="Saraceni, V" uniqKey="Saraceni V">V Saraceni</name></author><author><name sortKey="Cavalcante, Sc" uniqKey="Cavalcante S">SC Cavalcante</name></author><author><name sortKey="Pacheco, Ag" uniqKey="Pacheco A">AG Pacheco</name></author><author><name sortKey="Moulton, Lh" uniqKey="Moulton L">LH Moulton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lawn, Sd" uniqKey="Lawn S">SD Lawn</name></author><author><name sortKey="Wood, R" uniqKey="Wood R">R Wood</name></author><author><name sortKey="Cock, Kmd" uniqKey="Cock K">KMD Cock</name></author><author><name sortKey="Kranzer, K" uniqKey="Kranzer K">K Kranzer</name></author><author><name sortKey="Lewi, Jj" uniqKey="Lewi J">JJ Lewi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Churchyard, Gj" uniqKey="Churchyard G">GJ Churchyard</name></author><author><name sortKey="Fielding, K" uniqKey="Fielding K">K Fielding</name></author><author><name sortKey="Charalambous, S" uniqKey="Charalambous S">S Charalambous</name></author><author><name sortKey="Day, Jh" uniqKey="Day J">JH Day</name></author><author><name sortKey="Corbett, El" uniqKey="Corbett E">EL Corbett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wolday, D" uniqKey="Wolday D">D Wolday</name></author><author><name sortKey="Hailu, B" uniqKey="Hailu B">B Hailu</name></author><author><name sortKey="Girma, M" uniqKey="Girma M">M Girma</name></author><author><name sortKey="Hailu, E" uniqKey="Hailu E">E Hailu</name></author><author><name sortKey="Sanders, E" uniqKey="Sanders E">E Sanders</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moore, D" uniqKey="Moore D">D Moore</name></author><author><name sortKey="Liechty, C" uniqKey="Liechty C">C Liechty</name></author><author><name sortKey="Ekwarua, P" uniqKey="Ekwarua P">P Ekwarua</name></author><author><name sortKey="Werea, W" uniqKey="Werea W">W Werea</name></author><author><name sortKey="Mwimaa, G" uniqKey="Mwimaa G">G Mwimaa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perez, A" uniqKey="Perez A">A Perez</name></author><author><name sortKey="Brown, Hs" uniqKey="Brown H">HS Brown</name></author><author><name sortKey="Restrepo, Bi" uniqKey="Restrepo B">BI Restrepo</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23762214</article-id><article-id pub-id-type="pmc">3660598</article-id><article-id pub-id-type="publisher-id">PONE-D-12-39353</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0064488</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Survey Research</subject></subj-group></subj-group><subj-group><subject>Epidemiology</subject><subj-group><subject>Clinical Epidemiology</subject><subject>Epidemiological Methods</subject><subject>Infectious Disease Epidemiology</subject><subject>Survey Methods</subject></subj-group></subj-group><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group><subj-group><subject>Viral Diseases</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV diagnosis and management</subject><subject>HIV epidemiology</subject><subject>HIV opportunistic infections</subject></subj-group></subj-group></subj-group><subj-group><subject>Infectious Disease Control</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Determinant Factors Associated with Occurrence of Tuberculosis among Adult People Living with HIV after Antiretroviral Treatment Initiation in Addis Ababa, Ethiopia: A Case Control Study</article-title><alt-title alt-title-type="running-head">Factors of Tuberculosis in People Living with HIV</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kibret</surname><given-names>Kelemu Tilahun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yalew</surname><given-names>Alemayehu Worku</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Belaineh</surname><given-names>Belaineh Girma</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Asres</surname><given-names>Muluken Melese</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Public Health, College of Medical and Health Science, Wollega University, Nekemte, Ethiopia</addr-line></aff><aff id="aff2"><label>2</label><addr-line>School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Help Ethiopia Address Low TB Performance (HEAL TB) Project, USAID/Management Sciences for Health (MSH), Addis Ababa, Ethiopia</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Caylà</surname><given-names>Joan A.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>Public Health Agency of Barcelona, Spain</addr-line></aff><author-notes><corresp id="cor1">* E-mail: <email>ktwu27@gmail.com</email></corresp><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: KTK AWY BGB MMA. Performed the experiments: KTK AWY BGB MMA. Analyzed the data: KTK AWY BGB MMA. Contributed reagents/materials/analysis tools: KTK AWY BGB MMA. Wrote the paper: KTK AWY BGB MMA.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>5</month><year>2013</year></pub-date><pub-date pub-type="ecorrected"><day>6</day><month>6</month><year>2013</year></pub-date><volume>8</volume><issue>5</issue><elocation-id>e64488</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2013</year></date></history><permissions><copyright-year>2013</copyright-year><copyright-holder>Kibret et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Tuberculosis (TB) is a leading morbidity and mortality, and the first presenting sign in majority of people living with Human Immune deficiency Virus (PLWH). Determinants of active TB among HIV patients on anti retroviral treatment (ART) are not well described in resource limited settings. The aim of this study was to assess determinant factors for the occurrence of TB among people living with HIV after ART initiation in public hospitals and health centers in Addis Ababa, Ethiopia.</p></sec><sec><title>Methods and Findings</title><p>A case control study was conducted from December 2011 to February 2012 in 2 public hospitals and 13 health centers in Addis Ababa. The study population consisted of 204 cases and 409 controls. Cases were adult people living with HIV who developed TB after ART initiation and controls were adult people living with HIV who did not develop TB after ART initiation. An interviewer administered structured questionnaire was used to collect information.</p><p>After adjustment for potential confounders, presence of isoniazid prophylaxis (adjusted odd ratio [AOR] 0.35, 95% confidence interval [CI] 0.125, 0.69) and cotrimoxazole prophylaxis (AOR = 0.19; 95% CI: 0.06, 0.62) had protective benefit against risk of TB. In contrary, bedridden (AOR = 9.36; 95% CI: 3.39, 25.85), having World Health Organization (WHO) clinical stage III/IV (AOR = 3.40; 95% CI: 1.69, 6.87) and hemoglobin level <10 mg/dl (AOR = 7.43; 95% CI; 3.04, 18.31) at enrollment to ART care were predictors for increased risk of tuberculosis in PLWH after ART initiation.</p></sec><sec><title>Conclusion</title><p>Increasing coverage of isoniazid preventive therapy and cotrimoxazole preventive therapy reduced risk of TB among HIV patients who started treatment. All PLWH should be screened for TB, but for patients who have advanced disease condition (WHO clinical stage III/IV, being bedridden and having hemoglobin level <10 mg/dl) intensified screening is highly recommended during treatment follow up.</p></sec></abstract><funding-group><funding-statement>The United States Agency for International Development (USAID) funded this article. The views expressed in this publication are the responsibility of authors and do not necessarily reflect the views of USAID or the United States Government. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"></page-count></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In high HIV prevalence population, tuberculosis (TB) is a leading cause of morbidity and mortality, and the first presenting sign in the majority of acquired immune deficiency syndrome (AIDS) patients <xref ref-type="bibr" rid="pone.0064488-Preliminary1">[1]</xref>, <xref ref-type="bibr" rid="pone.0064488-Federal1">[2]</xref>. It is also the most common presenting illness among people living with HIV, including those who are taking antiretroviral treatment (ART) <xref ref-type="bibr" rid="pone.0064488-World1">[3]</xref>–<xref ref-type="bibr" rid="pone.0064488-World2">[5]</xref>. Despite major reductions with ART, however, risk of TB remains high in Africa <xref ref-type="bibr" rid="pone.0064488-World3">[6]</xref>.</p><p>According to the 2012 World Health Organization (WHO) global TB control report, Ethiopia ranks 8<sup>th</sup> among the 22 high-burden countries in the world and the prevalence rate of TB including HIV positive TB (HIV+TB) is 237 per 1000,000 population with incidence rate of 258/100000 in 2011. There were 8% of HIV+TB patients in the country. The incidence rate of HIV+TB patients is 45/100000 <xref ref-type="bibr" rid="pone.0064488-World4">[7]</xref> and number of TB case is more likely to increase in the country as HIV/AIDS epidemic expands <xref ref-type="bibr" rid="pone.0064488-World5">[8]</xref>.</p><p>The life time risk of developing active TB in HIV-negative individuals is approximately 10%, but the annual risk among HIV-infected patients is ∼10%, while the lifetime risk approaches 50% among them <xref ref-type="bibr" rid="pone.0064488-Habib1">[9]</xref>. It is estimated that about one-third of people with HIV are also infected with TB <xref ref-type="bibr" rid="pone.0064488-Preliminary1">[1]</xref>. Even though ART is known to decrease incidence of TB, still studies have reported TB incidence from HIV patients on ART <xref ref-type="bibr" rid="pone.0064488-Bonnet1">[10]</xref>–<xref ref-type="bibr" rid="pone.0064488-Joshua2">[15]</xref>.</p><p>In developing countries incidence of TB occurrence has been associated with factors like socio-economic <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>–<xref ref-type="bibr" rid="pone.0064488-Lnnroth1">[21]</xref>, lifestyle/habits <xref ref-type="bibr" rid="pone.0064488-Lienhardt1">[17]</xref>, <xref ref-type="bibr" rid="pone.0064488-Lnnroth1">[21]</xref>, <xref ref-type="bibr" rid="pone.0064488-Rehm1">[22]</xref>, clinical <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>, <xref ref-type="bibr" rid="pone.0064488-Komati1">[23]</xref>–<xref ref-type="bibr" rid="pone.0064488-Churchyard1">[27]</xref>, laboratory <xref ref-type="bibr" rid="pone.0064488-Bonnet1">[10]</xref>, <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>, <xref ref-type="bibr" rid="pone.0064488-Hermans1">[19]</xref>, <xref ref-type="bibr" rid="pone.0064488-Wolday1">[28]</xref>, <xref ref-type="bibr" rid="pone.0064488-Moore1">[29]</xref> and other co-morbidities, example, diabetes <xref ref-type="bibr" rid="pone.0064488-Perez1">[30]</xref>. Many patients either have a history of TB when they start ART, or they develop TB while receiving ART in the developing world <xref ref-type="bibr" rid="pone.0064488-World3">[6]</xref>. It has not been well delineated what factors influence the development of TB in patients on ART <xref ref-type="bibr" rid="pone.0064488-Komati1">[23]</xref>. In sub-Saharan Africa including Ethiopia, the incidence of tuberculosis in adults receiving highly active antiretroviral therapy (HAART) is higher than in HIV-negative adults <xref ref-type="bibr" rid="pone.0064488-World1">[3]</xref>. Studies on risk factors of TB were done in the general population but determinants of active TB among HIV patients are not well described in resource limited settings. There are no enough studies in Ethiopia on factors associated with development of TB among HIV infected patients who started ART. This study assessed the determinant factors for the occurrence of TB in people living with HIV (PLWHIV) who were already enrolled on ART in public hospitals and health centers, Addis Ababa.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>From December 2011 to February 2012 this case control study was conducted in two hospitals and thirteen health centers in Addis Ababa, the capital city of Ethiopia and seat of African Union & Economic Commission for Africa.</p><p>Cases were defined as adult people living with HIV who developed TB after ART initiation and on anti TB treatment in the last 6 months before data collection and controls were adults living with HIV who did not develop TB after ART initiation. Diagnosis of TB in HIV-positive patients was made based on the national TB guideline <xref ref-type="bibr" rid="pone.0064488-Federal2">[31]</xref>.</p><p><bold>Smear positive pulmonary tuberculosis (PTB+)</bold> diagnosed if one sputum smear examination positive for Acid Fast Bacilli (AFB) by direct microscopy, <bold>and</bold> laboratory confirmation of HIV infection. And <bold>smear negative pulmonary tuberculosis (PTB−)</bold> diagnosed if at least two sputum specimens negative for AFB and radio graphical abnormalities were consistent with active tuberculosis and laboratory confirmation of HIV infection and decision by a clinician to treat with a full course of anti tuberculosis chemotherapy. <bold>Extra-pulmonary tuberculosis</bold> diagnosed if one specimen from an extra-pulmonary site culture-positive for <italic>mycobacterium tuberculosis</italic> or smear-positive for AFB <bold>or</bold> histological or strong clinical evidence consistent with active extra-pulmonary tuberculosis <bold>and</bold> laboratory confirmation of HIV infection <bold>or</bold> strong clinical evidence of HIV infection <bold>and</bold> decision by a clinician to treat with a full course of anti tuberculosis chemotherapy</p><p>People living with HIV who were ≥18 years of age and started ART treatment and have follow up at the study sites were included in this study. People lining with HIV who presented with TB before commencing ART, taking TB therapy at the time of HAART initiation, not on ART or discontinued, and severely ill were excluded.</p><sec id="s2a"><title>Sample size determination</title><p>The sample size was calculated using Epi Info version 3.5.1 software (Center for Disease Control and Prevention, Atlanta, 2004) using the following parameters: proportion of CD4<50 cells/µl of 31.8% among the controls and 43.9% among cases <xref ref-type="bibr" rid="pone.0064488-VanRie1">[32]</xref>, 5% significance level, power of 80%, a case to control ratio of 1∶2 and by using the two proportion formula. The calculated sample size was 186 for cases and 372 for controls, adding 10% for none response, the resulting minimum sample size was 613 (204 cases and 409 controls). Sample size was calculated for exposure status in different variables of the most significant predictors of TB. First the sample size was calculated for exposure status in different variables; body mass index (BMI<18 kg/m<sup>2</sup>), CD4<50 cell/µl, and low Hgb level. We took the largest sample among these most significant predictors of TB in most literatures that is CD4 cell count less than 50 cell/µl as exposure variable.</p></sec><sec id="s2b"><title>Sampling Technique/Procedure</title><p>First, the governmental hospitals and health centers were assessed whether they have adequate cases or not. Two hospitals and thirteen health centers were found to be eligible and included in the study purposely to get adequate number of cases. Identification of cases and controls was done by the principal investigator through the help of the ART and TB registries. All TB–HIV patients on ART who were on anti TB treatment (cases) and fulfilled inclusion criteria were included in the study for their relative small number. Since controls were adequate enough to be sampled, they were selected by simple random sampling method. For those controls that fulfill inclusion criteria, unique identification numbers were given in increasing order by using the registries. Then simple random sampling technique was employed to select samples from each facility. Controls were allocated and selected from each facility based on the number of cases available in each facility with the control to case ratio of 2∶1. I.e. for each case two controls.</p></sec><sec id="s2c"><title>Data Collection and analysis</title><p>The data were collected by trained nurses using structured questionnaire, which was translated into Amharic from English, back translated and pre-tested for consistency. The data were collected from two sources: the primary data collected by face to face interview of patients to asses: Socio demographical variables, (age, sex, religion, ethnicity, marital status, employment and educational status), use of substances such as smoking, alcohol and Chat/Khat, medical history like presence of asthma and history of diabetes mellitus, contact history with a TB patient in the family, living conditions (e.g. persons per household (crowding), availability of separate kitchen in the house hold, having latrine in the compound). And to supplement clinical and laboratory information at the ART initiation variables like (CD4 cell count (cells/µL), hemoglobin level mg/dl, WHO clinical stage, functional status, opportunistic infection, chemoprophylaxis) extracted from ART card and log books.</p><p>Data were entered and cleaned using Epi-info version 3.5.1 and exported to SPSS software version 16 for analysis. Frequencies and proportions were used to describe the study population in relation to relevant variables. Bivariate analysis was performed to examine the effect of each variable of interest on the risk of TB. Crude odds ratios (COR) and their 95% confidence intervals (CIs) were estimated using binary logistic regression, with TB as an outcome. To identify confounding factors and to measure the independent effects of each exposure variable on occurrence of tuberculosis, a multivariate logistic regression model was used with the variables having a p-value <0.05 in the bivariate analysis. To decide whether the model adequately describes the data, we used the Hosmer-Lemeshow test which indicates a poor fit if the significance value (p) is less than 0.05 and good fit greater than 0.05. Here, in this study the model adequately fits the data since p-value is 0.78.</p></sec><sec id="s2d"><title>Ethical issues</title><p>Ethical clearance was obtained from the Institutional Review Board (IRB) of the Addis Ababa University, College of Health science, School of Public Health and from Addis Ababa City Health Bureau Ethics Review committee. Since there were illiterate study participants, the data collectors inform each respondent and confirmed the willingness of the participants by signing on the informed consent sheet. So that consent was obtained from each study participants and confidentiality assured for all the information provided. Moreover, personal identifiers were not included on questionnaire.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Socio-demographic, clinical and immunological characteristics of study participants</title><p>Of 613 participants selected, 593 study subjects responded (196 (33%) cases and 397(67%) controls) with over all response rates of 96.7% (96.1% for cases and 97.1% for controls).</p><p>The mean and inter quartile range (IQR) for the age of cases were 36.7 and 29–42.75 years, respectively. The corresponding values for controls were 35.7 and 30–40 years. More proportions of case and control patients were in the age group of 30–39; 37.2% and 45.6% respectively. High proportions of women were repoted in both groups; 56.6% (111) in cases and 69.3% (275) in controls respectively. More than three fourth of the patients have completed primary school and above; 83.2% in cases and 80.9% in controls. The majority of subjects; 60.2% in cases and 59.9% in controls were single and widowed/divorced.</p><p>Majority of cases; 78.4% (152) were in WHO clinical stage III or IV. In contrary, 55.5% (213) control groups were in WHO clinical stage I or II. During ART initiation 85% of cases and 64.9% of controls did not use INH preventive therapy. Of the total 183 patients in cases; three fourth, 73.2% of patients had CD4+ cell count less than 200 cells/µl. But half, 53.6% of patients in controls had CD4+ cell count less than 200 cells/µl. Among cases; 39% of them had Hgb level less than 10 mg/dl. In contrary, 7.2% of controls had Hgb level less than 10 mg/dl <bold>(</bold><xref ref-type="table" rid="pone-0064488-t001"><bold>Table 1</bold></xref><bold>)</bold>.</p><table-wrap id="pone-0064488-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064488.t001</object-id><label>Table 1</label><caption><title>Socio-demographic, clinical and immunological characteristics of study participants in Addis Ababa, 2012.</title></caption><alternatives><graphic id="pone-0064488-t001-1" xlink:href="pone.0064488.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Variables</td><td align="left" rowspan="1" colspan="1">Cases n(%)</td><td align="left" rowspan="1" colspan="1">Controls n(%)</td><td align="left" rowspan="1" colspan="1">Total n (%)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="left" rowspan="1" colspan="1">Male</td><td align="justify" rowspan="1" colspan="1">85(43.4)</td><td align="justify" rowspan="1" colspan="1">122(30.7)</td><td align="justify" rowspan="1" colspan="1">207(34.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Female</td><td align="justify" rowspan="1" colspan="1">111(56.6)</td><td align="justify" rowspan="1" colspan="1">275(69.3)</td><td align="justify" rowspan="1" colspan="1">386(65.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold></td><td align="left" rowspan="1" colspan="1">≥40</td><td align="justify" rowspan="1" colspan="1">70(35.)</td><td align="justify" rowspan="1" colspan="1">120(30.2)</td><td align="justify" rowspan="1" colspan="1">149(25.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">30–39</td><td align="justify" rowspan="1" colspan="1">73(37.2)</td><td align="justify" rowspan="1" colspan="1">181(45.6)</td><td align="justify" rowspan="1" colspan="1">254(42.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">18–29</td><td align="justify" rowspan="1" colspan="1">53(27)</td><td align="justify" rowspan="1" colspan="1">96(24.2)</td><td align="justify" rowspan="1" colspan="1">190(32.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Education</bold></td><td align="left" rowspan="1" colspan="1">No education</td><td align="justify" rowspan="1" colspan="1">33 (16.8)</td><td align="justify" rowspan="1" colspan="1">76 (19.1)</td><td align="justify" rowspan="1" colspan="1">109 (18.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Primary</td><td align="justify" rowspan="1" colspan="1">85 (43.4)</td><td align="justify" rowspan="1" colspan="1">159 (40.1)</td><td align="justify" rowspan="1" colspan="1">244 (41.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Secondary</td><td align="justify" rowspan="1" colspan="1">61 (31.1)</td><td align="justify" rowspan="1" colspan="1">122 (30.7)</td><td align="justify" rowspan="1" colspan="1">183 (30.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Tertiary</td><td align="justify" rowspan="1" colspan="1">17 (8.7)</td><td align="justify" rowspan="1" colspan="1">40 (10.1)</td><td align="justify" rowspan="1" colspan="1">57(9.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Marital status</bold></td><td align="left" rowspan="1" colspan="1">Married</td><td align="justify" rowspan="1" colspan="1">78(39.8)</td><td align="justify" rowspan="1" colspan="1">159(40.1)</td><td align="justify" rowspan="1" colspan="1">237(40.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Divorced/Widowed</td><td align="justify" rowspan="1" colspan="1">55(28.1)</td><td align="justify" rowspan="1" colspan="1">145(36.5)</td><td align="justify" rowspan="1" colspan="1">200(33.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Single</td><td align="justify" rowspan="1" colspan="1">63(32.1)</td><td align="justify" rowspan="1" colspan="1">93(23.4)</td><td align="justify" rowspan="1" colspan="1">156(26.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>WHO Clinical Stage</bold></td><td align="left" rowspan="1" colspan="1">Stage III or IV</td><td align="justify" rowspan="1" colspan="1">152(78.4)</td><td align="justify" rowspan="1" colspan="1">171(44.5)</td><td align="justify" rowspan="1" colspan="1">323(55.88)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Stage I or II</td><td align="justify" rowspan="1" colspan="1">42(21.6)</td><td align="justify" rowspan="1" colspan="1">213(55.5)</td><td align="justify" rowspan="1" colspan="1">255(44.12)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INH prophylaxis</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="justify" rowspan="1" colspan="1">27(15.0)</td><td align="justify" rowspan="1" colspan="1">137(35.1)</td><td align="justify" rowspan="1" colspan="1">164(28.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="justify" rowspan="1" colspan="1">153 (85.0)</td><td align="justify" rowspan="1" colspan="1">253 (64.9)</td><td align="justify" rowspan="1" colspan="1">406 (71.2)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CTX prophylaxis</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="justify" rowspan="1" colspan="1">164 (87.2)</td><td align="justify" rowspan="1" colspan="1">380 (96.2)</td><td align="justify" rowspan="1" colspan="1">544 (93.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="justify" rowspan="1" colspan="1">24(12.8)</td><td align="justify" rowspan="1" colspan="1">15(3.8)</td><td align="justify" rowspan="1" colspan="1">36(6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hgb level (mg/dl)</bold></td><td align="left" rowspan="1" colspan="1"><10</td><td align="justify" rowspan="1" colspan="1">73(39.0)</td><td align="justify" rowspan="1" colspan="1">28(7.2)</td><td align="justify" rowspan="1" colspan="1">101(17.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">10–12.49</td><td align="justify" rowspan="1" colspan="1">54(28.9)</td><td align="justify" rowspan="1" colspan="1">118(30.4)</td><td align="justify" rowspan="1" colspan="1">172 (29.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">> = 12.5</td><td align="justify" rowspan="1" colspan="1">60(32.1)</td><td align="justify" rowspan="1" colspan="1">242(62.4)</td><td align="justify" rowspan="1" colspan="1">302(52.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4 cell count (cell/µL)</bold></td><td align="left" rowspan="1" colspan="1">≤50</td><td align="justify" rowspan="1" colspan="1">26(13.9)</td><td align="justify" rowspan="1" colspan="1">22(5.6)</td><td align="justify" rowspan="1" colspan="1">48(8.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">51–200</td><td align="justify" rowspan="1" colspan="1">112(59.9)</td><td align="justify" rowspan="1" colspan="1">187(47.7)</td><td align="justify" rowspan="1" colspan="1">299(51.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">201–349</td><td align="justify" rowspan="1" colspan="1">33(17.6)</td><td align="justify" rowspan="1" colspan="1">109(27.8)</td><td align="justify" rowspan="1" colspan="1">142(24.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">≥350</td><td align="justify" rowspan="1" colspan="1">16(8.6)</td><td align="justify" rowspan="1" colspan="1">74(18.9)</td><td align="justify" rowspan="1" colspan="1">90(15.5)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>WHO = World Health Organization, INH = Isoniazid, CTX = Cotrimoxazole, Hgb = Hemoglobin.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Clinical presentation of Tuberculosis in HIV positive persons after ART initiation</title><p>Half, 50.5% (99) of the TB patients presented with smear negative pulmonary TB followed by extra pulmonary TB, 31.1% (61) and 18.4% (36) patients had smear positive pulmonary TB.</p></sec><sec id="s3c"><title>Bivariate analysis of factors associated with TB</title><p>The bivariate analysis showed that higher proportion of male patients (COR = 1.73; 95% CI: 1.23, 2.46) develop TB compared to female patients. The divorced/widowed (COR = 0.560; 95% CI: 0.36, 0.87) patients were less likely to develop TB compared with unmarried (single) individuals. But educational status and occupation were not associated with occurrence of Tuberculosis <bold>(</bold><xref ref-type="table" rid="pone-0064488-t002"><bold>Table 2</bold></xref><bold>)</bold>.</p><table-wrap id="pone-0064488-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064488.t002</object-id><label>Table 2</label><caption><title>Socio-demographic determinant factors for occurrence of TB among people living with HIV after ART initiation: comparison of TB cases and controls by bivariate analysis in Binary logistic regression, Addis Ababa, 2012.</title></caption><alternatives><graphic id="pone-0064488-t002-2" xlink:href="pone.0064488.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Variables</td><td align="left" rowspan="1" colspan="1">Cases n(%)</td><td align="left" rowspan="1" colspan="1">Controls n(%)</td><td align="left" rowspan="1" colspan="1">COR</td><td align="left" rowspan="1" colspan="1">95% CI</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">85(43.4)</td><td align="left" rowspan="1" colspan="1">122(30.7)</td><td align="left" rowspan="1" colspan="1">1.73</td><td align="left" rowspan="1" colspan="1">1.21, 2.46</td><td align="left" rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="nt102">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">111(56.6)</td><td align="left" rowspan="1" colspan="1">275(69.3)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold></td><td align="left" rowspan="1" colspan="1">≥40</td><td align="left" rowspan="1" colspan="1">70(35.)</td><td align="left" rowspan="1" colspan="1">120(30.2)</td><td align="left" rowspan="1" colspan="1">1.057</td><td align="left" rowspan="1" colspan="1">0.68, 1.65</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">30–39</td><td align="left" rowspan="1" colspan="1">73(37.2)</td><td align="left" rowspan="1" colspan="1">181(45.6)</td><td align="left" rowspan="1" colspan="1">0.731</td><td align="left" rowspan="1" colspan="1">0.47, 1.13</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">18–29</td><td align="left" rowspan="1" colspan="1">53(27)</td><td align="left" rowspan="1" colspan="1">96(24.2)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Education</bold></td><td align="left" rowspan="1" colspan="1">No education</td><td align="left" rowspan="1" colspan="1">33 (16.8)</td><td align="left" rowspan="1" colspan="1">76 (19.1)</td><td align="left" rowspan="1" colspan="1">1.02</td><td align="left" rowspan="1" colspan="1">0.508,2.06</td><td align="left" rowspan="1" colspan="1">0.952</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Primary</td><td align="left" rowspan="1" colspan="1">85 (43.4)</td><td align="left" rowspan="1" colspan="1">159 (40.1)</td><td align="left" rowspan="1" colspan="1">1.26</td><td align="left" rowspan="1" colspan="1">0.673,2.35</td><td align="left" rowspan="1" colspan="1">0.472</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Secondary</td><td align="left" rowspan="1" colspan="1">61 (31.1)</td><td align="left" rowspan="1" colspan="1">122 (30.7)</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">0.617,2.24</td><td align="left" rowspan="1" colspan="1">0.622</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Tertiary</td><td align="left" rowspan="1" colspan="1">17 (8.7)</td><td align="left" rowspan="1" colspan="1">40 (10.1)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Marital status</bold></td><td align="left" rowspan="1" colspan="1">Married</td><td align="left" rowspan="1" colspan="1">78(39.8)</td><td align="left" rowspan="1" colspan="1">159(40.1)</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">0.48–1.10</td><td align="left" rowspan="1" colspan="1">0.131</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Divorced/Widowed</td><td align="left" rowspan="1" colspan="1">55(28.1)</td><td align="left" rowspan="1" colspan="1">145(36.5)</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.36, 0.87</td><td align="left" rowspan="1" colspan="1">0.011<xref ref-type="table-fn" rid="nt102">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Single</td><td align="left" rowspan="1" colspan="1">63(32.1)</td><td align="left" rowspan="1" colspan="1">93(23.4)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Occupation</bold></td><td align="left" rowspan="1" colspan="1">Employed</td><td align="left" rowspan="1" colspan="1">57(29.1)</td><td align="left" rowspan="1" colspan="1">125(31.5)</td><td align="left" rowspan="1" colspan="1">0.892</td><td align="left" rowspan="1" colspan="1">0.61,1.30</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Unemployed</td><td align="left" rowspan="1" colspan="1">139(70.9)</td><td align="left" rowspan="1" colspan="1">272 (68.5)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label>*</label><p><bold>Significant at α = 0.05</bold>.</p></fn></table-wrap-foot></table-wrap><p>The cases are more likely to be smoker (COR = 3.34; 95% CI: 2.087, 5.35), alcohol drinker (COR = 2.39; 95% CI: 1.63, 3.52) as well as chat chewer (COR = 2.31; 95% CI: 1.57, 3.40). But Tuberculosis is not associated with diabetes (COR = 1.893; 95% CI: 0.54, 6.62) and history of asthma (COR = 1.3030; 95% CI: 0.59, 2.87). Patients who lived in other place for at least 6 months were about 1.7 times more likely to develop TB after ART initiation (p = 0.017). In addition, controls were more likely to have separate kitchen (p = 0.032) and latrine (p = 0.02). Using gas/kerosene as a source of energy in house hold associated with increased risk of TB (COR = 2.5; 95% CI: 1.74, 3.61). Those who lived in households having a size of 6–10 members were more likely to develop TB compared with the number of persons in the household between 1 and 5 (COR = 1.914; 95% CI: 1.23, 2.99). Similarly, the number of adults in the household between 6 and 10 were 1.89 times more likely to develop TB than adults in the household between 1 and 5 (<italic>P</italic> = 0.043). But, previous family history of TB, history of imprisoned, living in his/her own or family's house and house floor made of cement or mud did not show significant difference between cases and controls <bold>(</bold><xref ref-type="table" rid="pone-0064488-t003"><bold>Table 3</bold></xref><bold>)</bold>.</p><table-wrap id="pone-0064488-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064488.t003</object-id><label>Table 3</label><caption><title>Host and environmental determinant factors for occurrence of TB among HIV patients after ART initiation, Addis Ababa, 2012.</title></caption><alternatives><graphic id="pone-0064488-t003-3" xlink:href="pone.0064488.t003"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Variables</td><td align="left" rowspan="1" colspan="1">Cases n(%)</td><td align="left" rowspan="1" colspan="1">Controls n(%)</td><td align="left" rowspan="1" colspan="1">COR</td><td align="left" rowspan="1" colspan="1">95% CI</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Chat chewing</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">70 (35.7)</td><td align="left" rowspan="1" colspan="1">77 (19.4)</td><td align="left" rowspan="1" colspan="1">2.31</td><td align="left" rowspan="1" colspan="1">1.57, 3.40</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">126 (64.3)</td><td align="left" rowspan="1" colspan="1">320 (80.6)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Smoking</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">49(25.0)</td><td align="left" rowspan="1" colspan="1">36(9.1)</td><td align="left" rowspan="1" colspan="1">3.34</td><td align="left" rowspan="1" colspan="1">2.087,5.35</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">147 (75.0)</td><td align="left" rowspan="1" colspan="1">361(90.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Alcohol drinking</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">71 (36.2)</td><td align="left" rowspan="1" colspan="1">76 (19.1)</td><td align="left" rowspan="1" colspan="1">2.39</td><td align="left" rowspan="1" colspan="1">1.63, 3.52</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">125 (63.8)</td><td align="left" rowspan="1" colspan="1">321 (80.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TB history</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">63 (32.1)</td><td align="left" rowspan="1" colspan="1">108 (27.2)</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">0.74,1.59</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">120 (61.2)</td><td align="left" rowspan="1" colspan="1">223(56.2)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Asthma</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">11(5.6)</td><td align="left" rowspan="1" colspan="1">16(4.0)</td><td align="left" rowspan="1" colspan="1">1.303</td><td align="left" rowspan="1" colspan="1">0.59, 2.87</td><td align="left" rowspan="1" colspan="1">0.511</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">181(92.3)</td><td align="left" rowspan="1" colspan="1">343(86.4)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Diabetes mellitus</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">5 (2.6)</td><td align="left" rowspan="1" colspan="1">5(1.3)</td><td align="left" rowspan="1" colspan="1">1.893</td><td align="left" rowspan="1" colspan="1">0.54, 6.62</td><td align="left" rowspan="1" colspan="1">0.318</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">187(95.4)</td><td align="left" rowspan="1" colspan="1">354(89.2)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Family Hx of TB</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">33(16.8)</td><td align="left" rowspan="1" colspan="1">75(18.9)</td><td align="left" rowspan="1" colspan="1">0.847</td><td align="left" rowspan="1" colspan="1">0.54, 1.33</td><td align="left" rowspan="1" colspan="1">0.471</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">159(81.1)</td><td align="left" rowspan="1" colspan="1">306(77.1)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Imprisoned</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">15(7.7)</td><td align="left" rowspan="1" colspan="1">39(9.8)</td><td align="left" rowspan="1" colspan="1">0.761</td><td align="left" rowspan="1" colspan="1">0.41, 1.42</td><td align="left" rowspan="1" colspan="1">0.389</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">181(92.3)</td><td align="left" rowspan="1" colspan="1">358 (90.2)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Have kitchen</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">109(55.6)</td><td align="left" rowspan="1" colspan="1">257(64.7)</td><td align="left" rowspan="1" colspan="1">0.682</td><td align="left" rowspan="1" colspan="1">0.481,0.97</td><td align="left" rowspan="1" colspan="1">0.032<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">87(44.4%)</td><td align="left" rowspan="1" colspan="1">140(35.3)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Owen house</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">52 (26.5)</td><td align="left" rowspan="1" colspan="1">137 (34.5)</td><td align="left" rowspan="1" colspan="1">0.685</td><td align="left" rowspan="1" colspan="1">0.47,1.00</td><td align="left" rowspan="1" colspan="1">0.05<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">144(73.5)</td><td align="left" rowspan="1" colspan="1">260(65.5)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Latrine</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">160(81.6)</td><td align="left" rowspan="1" colspan="1">352(88.7)</td><td align="left" rowspan="1" colspan="1">0.568</td><td align="left" rowspan="1" colspan="1">0.35, 0.94</td><td align="left" rowspan="1" colspan="1">0.02<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">36 (18.4)</td><td align="left" rowspan="1" colspan="1">45 (11.3)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>kerosene as source of energy in HH</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">139(70.9)</td><td align="left" rowspan="1" colspan="1">196(49.4)</td><td align="left" rowspan="1" colspan="1">2.501</td><td align="left" rowspan="1" colspan="1">1.74, 3.61</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">57(29.1)</td><td align="left" rowspan="1" colspan="1">201(50.6)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Number of people living in HH</bold></td><td align="left" rowspan="1" colspan="1">>10</td><td align="left" rowspan="1" colspan="1">3(1.5)</td><td align="left" rowspan="1" colspan="1">8(2.0)</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">0.22, 3.24</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">6–10</td><td align="left" rowspan="1" colspan="1">44(22.4)</td><td align="left" rowspan="1" colspan="1">52(13.1)</td><td align="left" rowspan="1" colspan="1">1.914</td><td align="left" rowspan="1" colspan="1">1.23, 2.99</td><td align="left" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="nt103">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1–5</td><td align="left" rowspan="1" colspan="1">149(76.0)</td><td align="left" rowspan="1" colspan="1">337(84.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Numbers of room</bold></td><td align="left" rowspan="1" colspan="1">1–2</td><td align="left" rowspan="1" colspan="1">153(78.5)</td><td align="left" rowspan="1" colspan="1">299(75.3)</td><td align="left" rowspan="1" colspan="1">1.194</td><td align="left" rowspan="1" colspan="1">0.79, 1.80</td><td align="left" rowspan="1" colspan="1">0.397</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">> = 3</td><td align="left" rowspan="1" colspan="1">42(21.5)</td><td align="left" rowspan="1" colspan="1">98(24.7)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label>*</label><p><bold>significant at α = 0.05</bold>.</p></fn><fn id="nt104"><p><bold>Hx = history</bold>.</p></fn><fn id="nt105"><p>HH = Houshold.</p></fn></table-wrap-foot></table-wrap><p>Other important predictors for the TB occurrence were base line clinical variables. TB patients are more likely to have baseline WHO clinical stage III or IV (COR = 4.51; 95% CI: 3.032, 6.70). Those study subjects with INH prophylaxis (COR = 0.32; 95% CI: 0.21, 0.52) and cotrimoxazole prophylaxis (COR = 0.27; 95% CI: 0.14, 0.53) were less likely to develop TB. Individuals with hemoglobin level <10 mg/dl were more likely to have TB than individuals with hemoglobin level ≥12.5 mg/dl (COR = 10.5; 95% CI: 6.26, 17.68). Patients who were bedridden (COR = 8.87; 95% CI: 4.91, 16.05) and ambulatory (COR = 17.7; 95% CI: 9.98, 31.39) by their functional status were at increased risk of developing TB compared to working status. Similarly, patients whose CD4 cell count ≤50 cell/µL were more likely to develop TB compared to patients who had ≥350 cell/µL cd4 cell count (COR = 5.47; 95% CI: 2.56, 11.97) <bold>(</bold><xref ref-type="table" rid="pone-0064488-t004"><bold>Table 4</bold></xref><bold>)</bold>.</p><table-wrap id="pone-0064488-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064488.t004</object-id><label>Table 4</label><caption><title>Clinical and immunological factors for occurrence of TB among HIV patients after ART initiation: bivariate analysis in Binary logistic regression, Addis Ababa, 2012.</title></caption><alternatives><graphic id="pone-0064488-t004-4" xlink:href="pone.0064488.t004"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Variables</td><td align="left" rowspan="1" colspan="1">Cases n(%)</td><td align="left" rowspan="1" colspan="1">Controls n(%)</td><td align="left" rowspan="1" colspan="1">COR</td><td align="left" rowspan="1" colspan="1">95% CI</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>WHO clinical stage</bold></td><td align="left" rowspan="1" colspan="1">Stage III orIV</td><td align="left" rowspan="1" colspan="1">152(78.4)</td><td align="left" rowspan="1" colspan="1">171(44.5)</td><td align="left" rowspan="1" colspan="1">4.51</td><td align="left" rowspan="1" colspan="1">3.032, 6.70</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Stage I or II</td><td align="left" rowspan="1" colspan="1">42(21.6)</td><td align="left" rowspan="1" colspan="1">213(55.5)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INH prophylaxis</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">27(15.0)</td><td align="left" rowspan="1" colspan="1">137(35.1)</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.21, 0.52</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">153 (85.0)</td><td align="left" rowspan="1" colspan="1">253 (64.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CTX prophylaxis</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">164 (87.2)</td><td align="left" rowspan="1" colspan="1">380 (96.2)</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.14, 0.53</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">24(12.8)</td><td align="left" rowspan="1" colspan="1">15(3.8)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Functional status</bold></td><td align="left" rowspan="1" colspan="1">Bed ridden</td><td align="left" rowspan="1" colspan="1">39(20.9)</td><td align="left" rowspan="1" colspan="1">20(5.1)</td><td align="left" rowspan="1" colspan="1">8.87</td><td align="left" rowspan="1" colspan="1">4.91, 16.05</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Ambulatory</td><td align="left" rowspan="1" colspan="1">70(37.4)</td><td align="left" rowspan="1" colspan="1">18(4.6)</td><td align="left" rowspan="1" colspan="1">17.7</td><td align="left" rowspan="1" colspan="1">9.98, 31.39</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Working</td><td align="left" rowspan="1" colspan="1">78(41.7)</td><td align="left" rowspan="1" colspan="1">355(90.3)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Opportunistic infection</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">110(59.8)</td><td align="left" rowspan="1" colspan="1">91(23.6)</td><td align="left" rowspan="1" colspan="1">4.80</td><td align="left" rowspan="1" colspan="1">3.29, 7.00</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">74(40.2)</td><td align="left" rowspan="1" colspan="1">294(76.4)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ART Regimen</bold></td><td align="left" rowspan="1" colspan="1">1b</td><td align="left" rowspan="1" colspan="1">45 (23.0)</td><td align="left" rowspan="1" colspan="1">35 (8.8)</td><td align="left" rowspan="1" colspan="1">3.75</td><td align="left" rowspan="1" colspan="1">1.96, 7.16</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1c</td><td align="left" rowspan="1" colspan="1">33(16.8)</td><td align="left" rowspan="1" colspan="1">115(29.0)</td><td align="left" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1">0.45, 1.54</td><td align="left" rowspan="1" colspan="1">0.566</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1d</td><td align="left" rowspan="1" colspan="1">38(19.4)</td><td align="left" rowspan="1" colspan="1">49(12.3)</td><td align="left" rowspan="1" colspan="1">2.26</td><td align="left" rowspan="1" colspan="1">1.197, 4.26</td><td align="left" rowspan="1" colspan="1">0.012<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1e</td><td align="left" rowspan="1" colspan="1">52(26.5)</td><td align="left" rowspan="1" colspan="1">109(27.5)</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">0.78, 2.48</td><td align="left" rowspan="1" colspan="1">0.246</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1f</td><td align="left" rowspan="1" colspan="1">5(2.6)</td><td align="left" rowspan="1" colspan="1">22(5.5)</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">0.23, 1.95</td><td align="left" rowspan="1" colspan="1">0.454</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1a</td><td align="left" rowspan="1" colspan="1">23 (11.7)</td><td align="left" rowspan="1" colspan="1">67 (16.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hgb level (mg/dl)</bold></td><td align="left" rowspan="1" colspan="1"><10</td><td align="left" rowspan="1" colspan="1">73(39.0)</td><td align="left" rowspan="1" colspan="1">28(7.2)</td><td align="left" rowspan="1" colspan="1">10.5</td><td align="left" rowspan="1" colspan="1">6.26, 17.68</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">10–12.49</td><td align="left" rowspan="1" colspan="1">54(28.9)</td><td align="left" rowspan="1" colspan="1">118(30.4)</td><td align="left" rowspan="1" colspan="1">1.85</td><td align="left" rowspan="1" colspan="1">1.20, 2.83</td><td align="left" rowspan="1" colspan="1"><0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">> = 12.5</td><td align="left" rowspan="1" colspan="1">60(32.1)</td><td align="left" rowspan="1" colspan="1">242(62.4)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4 count (cell/µL)</bold></td><td align="left" rowspan="1" colspan="1">≤50</td><td align="left" rowspan="1" colspan="1">26(13.9)</td><td align="left" rowspan="1" colspan="1">22(5.6)</td><td align="left" rowspan="1" colspan="1">5.47</td><td align="left" rowspan="1" colspan="1">2.56, 11.97</td><td align="left" rowspan="1" colspan="1"><0.0001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">51–200</td><td align="left" rowspan="1" colspan="1">112(59.9)</td><td align="left" rowspan="1" colspan="1">187(47.7)</td><td align="left" rowspan="1" colspan="1">2.77</td><td align="left" rowspan="1" colspan="1">1.54, 4.99</td><td align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="nt106">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">201–349</td><td align="left" rowspan="1" colspan="1">33(17.6)</td><td align="left" rowspan="1" colspan="1">109(27.8)</td><td align="left" rowspan="1" colspan="1">1.400</td><td align="left" rowspan="1" colspan="1">0.72, 2.73</td><td align="left" rowspan="1" colspan="1">0.322</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">≥350</td><td align="left" rowspan="1" colspan="1">16(8.6)</td><td align="left" rowspan="1" colspan="1">74(18.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label>*</label><p><bold>significant at α = 0.05</bold>.</p></fn><fn id="nt107"><p>WHO = World Health Organization, INH = Isoniazid, CTX = Cotrimoxazole, ART = Antiretroviral Therapy, Hgb = Hemoglobin, 1a = Stavudine, lamivudine, neverapine→d4t-3TC-NVP, 1b = Stavudine, lamivudine, efavirenz→d4t-3TC-EFV, 1c = Zidovudine, lamivudine, neverapine→AZT-3TC-NVP,1d = Zidovudine, lamivudine, efavirenz→AZT-3TC-EFV, 1e = TDF, lamivudine, efavirenz→TDF-3TC-EFV, 1f = TDF, lamivudine, neverapine→TDF-3TC-NVP.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title>Multivariate analysis: Factors independently associated with active TB</title><p>To identify independent predictors of developing tuberculosis, a multivariate logistic regression model was fitted with the variables having a p-value <0.05 in the bivariate analysis. So, some variables remained independent predictors for the occurrence of TB after controlling for the other factors. From these factors, being widowed or divorced were at lower risk of TB compared to single individuals (AOR = 0.36; 95% CI: 0.16, 0.82). Patients who had separate kitchen were less likely to have TB (AOR = 0.5; 95% CI: 0.26, 0.96; P<0.038). Presence of INH prophylaxis (AOR = 0.35; 95% CI: 0.125, 0.69; P = 0.005) and cotrimoxazole prophylaxis (AOR = 0.19; 95% CI: 0.06, 0.62) had an independent protective benefit against tuberculosis. Study subjects who were bedridden (AOR = 9.36; 95% CI: 3.39, 25.85) and ambulatory (AOR = 19.4; 95% CI: 7.44, 50.78) by their functional status were more likely to develop TB compared to working status. Study subjects with baseline WHO clinical stage III or IV had higher risk of developing TB (AOR = 3.4; 95% CI: 1.69, 6.87). As well individuals with hemoglobin level <10 mg/dl are more likely to develop TB than individuals with hemoglobin level ≥12.5 mg/dl (AOR = 7.43; 95% CI: 3.04, 18.31). Having opportunistic infection at ART initiation (AOR = 5.22; 95% CI: 2.67, 10.27), the ART regimen initiated at base line and using gas (kerosene) as energy source in the house hold (AOR = 2.67; 95% CI: 1.36, 5.2) were independently associated with increased risk of TB occurrence. But occupational status, smoking, alcohol intake, family history of TB, sex, lived other place, number of people living in the house hold and CD4 cell count lost their statistical significance in the multivariate analysis <bold>(</bold><xref ref-type="table" rid="pone-0064488-t005"><bold>Table 5</bold></xref><bold>)</bold>.</p><table-wrap id="pone-0064488-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064488.t005</object-id><label>Table 5</label><caption><title>Factors independently associated with active tuberculosis among HIV infected patients after ART initiation, Addis Ababa, 2012.</title></caption><alternatives><graphic id="pone-0064488-t005-5" xlink:href="pone.0064488.t005"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Variables</td><td align="left" rowspan="1" colspan="1">COR(95% CI)</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">AOR(95% CI)</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Kerosene as source of energy in HH</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">2.5(1.7, 3.6)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">2.67 (1.36, 5.2)</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Separate kitchen</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">0.68(0.48,0.9)</td><td align="left" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.50 (0.26,0.96)</td><td align="left" rowspan="1" colspan="1">0.038</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>WHO clinical stage</bold></td><td align="left" rowspan="1" colspan="1">Stage IIIorIV</td><td align="left" rowspan="1" colspan="1">4.508 (3.03,6.7)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">3.40 (1.69, 6.87)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Stage IorII</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INH preventive therapy</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">0.33(0.21,0.20)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">0.35 (0.125,0.69)</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CTX preventive therapy</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">0.27(0.14,0.53)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">0.19 (0.06, 0.62)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Functional status</bold></td><td align="left" rowspan="1" colspan="1">Bed ridden</td><td align="left" rowspan="1" colspan="1">8.88(4.91,16.05)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">9.36(3.39, 25.85)</td><td align="left" rowspan="1" colspan="1"><0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Ambulatory</td><td align="left" rowspan="1" colspan="1">17.8 (10,31.4)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">19.44(7.44,50.78)</td><td align="left" rowspan="1" colspan="1"><0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Working</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Opportunistic infection</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">4.80(3.29, 7.0)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">5.22 (2.67, 10.27)</td><td align="left" rowspan="1" colspan="1"><0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hgb level</bold></td><td align="left" rowspan="1" colspan="1"><10</td><td align="left" rowspan="1" colspan="1">10.52(6.26,17.7)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">7.43(3.04, 18.31)</td><td align="left" rowspan="1" colspan="1"><0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">10–12.49</td><td align="left" rowspan="1" colspan="1">1.85 (1.2, 2.83)</td><td align="left" rowspan="1" colspan="1"><0.0001</td><td align="left" rowspan="1" colspan="1">1.34 (0.65, 2.77)</td><td align="left" rowspan="1" colspan="1">0.430</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">≥12.5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Marital status</bold></td><td align="left" rowspan="1" colspan="1">Married</td><td align="left" rowspan="1" colspan="1">0.72 (0.48,1.1)</td><td align="left" rowspan="1" colspan="1">0.131</td><td align="left" rowspan="1" colspan="1">0.99 (0.48, 2.00)</td><td align="left" rowspan="1" colspan="1">0.985</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Divorced/widowed</td><td align="left" rowspan="1" colspan="1">0.56(0.36,0.87)</td><td align="left" rowspan="1" colspan="1">0.011</td><td align="left" rowspan="1" colspan="1">0.36 (0.16, 0.82)</td><td align="left" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Single</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>This case-control study has identified several determinant factors for the occurrence of TB among HIV infected people enrolled on ART in Addis Ababa. Housing condition, living standard and isoniazid preventive therapy were risk factors for TB in this setting. Patients who have advanced condition (WHO clinical stage III or IV disease, being bedridden and having hemoglobin level less than 10 mg/dl) were also associated with development of new TB infection.</p><p>In this study, among determinant factors, marital status was significantly associated with TB. Divorced or widowed Patients were less likely to develop TB compared to unmarried (single), which is consistent with other reports in West Africa and Ethiopia <xref ref-type="bibr" rid="pone.0064488-Lienhardt1">[17]</xref>, <xref ref-type="bibr" rid="pone.0064488-Solomon1">[33]</xref>. It might be explained by unmarried (single) persons are younger than married persons and have a different lifestyle, especially males, who often migrate to towns in search of a job where they live alone or with friends.</p><p>Similarly, low level of education was not associated with TB. But it is not consistent with the study from south west Ethiopia <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>. This could be due to the high prevalence of literates in our study population as it was from the capital of the country.</p><p>Smoking was identified as risk factor for the development of TB in clinic-based case-control study in West Africa <xref ref-type="bibr" rid="pone.0064488-Lienhardt1">[17]</xref>. But, in a case control study in Gambia, smoking was not associated with active TB <xref ref-type="bibr" rid="pone.0064488-HillPhilip1">[18]</xref>. Similarly, in this study smoking was not associated with TB occurrence in multivariate analysis. This could be due to the low prevalence of smoking in our study population. There could also be a social desirability bias whereby smokers denied their smoking status.</p><p>In a case control study from West Africa, history of asthma became protective against TB <xref ref-type="bibr" rid="pone.0064488-Lienhardt1">[17]</xref>. But, in this study history of asthma was not associated with TB. This is consistent with the case control study in Gambia <xref ref-type="bibr" rid="pone.0064488-HillPhilip1">[18]</xref>.</p><p>Studies demonstrated that contact with TB patients in the family associated with increased occurrence of TB <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>–<xref ref-type="bibr" rid="pone.0064488-HillPhilip1">[18]</xref>. But in this study family history of TB showed some degree of association with TB in bivariate analysis, but it did not have an independent effect on the occurrence TB in multivariate analysis when adjusted for other variables. This could be due to that the influence of TB history in the family as a risk factor for TB would differs by setting and background of HIV burden.</p><p>Other independent predictors of tuberculosis were WHO stage III or IV; patients with WHO stage III or IV have higher risk of developing TB than those with WHO stage I or II. It is consistent with other studies done in South Africa and South West Ethiopia <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>, <xref ref-type="bibr" rid="pone.0064488-Komati1">[23]</xref>. This suggests that who had WHO stage III or IV might be immune-compromised and predisposed to TB.</p><p>TB patients were 8.87 times more likely to be bedridden at the initiation of ART than working patients. This is consistent with the retrospective cohort study in Ethiopia <xref ref-type="bibr" rid="pone.0064488-Solomon1">[33]</xref>. High degree of suspicion while administering ART towards patients with this condition should be instituted.</p><p>Besides, availability of separate kitchen in the household associated with decreased risk of TB development which is consistent with a study from south west Ethiopia <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>. It might be explained by increased indoor air pollution if there is no separate cooking kitchen in the house. Likewise using gas (kerosene) as energy source in the household associated with TB as it was commonly used cooking fuels in urban areas.</p><p>Studies have shown that risk of TB was associated with the number of people living together in the household (over Crowding) <xref ref-type="bibr" rid="pone.0064488-HillPhilip1">[18]</xref>, <xref ref-type="bibr" rid="pone.0064488-Hermans1">[19]</xref>, <xref ref-type="bibr" rid="pone.0064488-Lnnroth1">[21]</xref>. But, this study did not find the association between TB and number of people in the household. This might be related to high proportions of unmarried persons in the study population resulted in low number of family size in the house hold. The other reason may be due to TB development is a reactivation of an infection acquired years ago due to HIV infection, with no relation to current living and crowding conditions.</p><p>In addition, patients having a hemoglobin level of ≤10 mg/dl have 2.4 times higher risk of developing TB than those patients having hemoglobin level ≥12.5 mg/dl, similar to other study findings in south west Ethiopia <xref ref-type="bibr" rid="pone.0064488-Taha1">[16]</xref>. This shows that patients having higher hemoglobin level were less likely to develop TB than those with low hemoglobin level. TB and hemoglobin level might be indirectly associated with advanced stage of HIV disease. When HIV positive patients have chronic disease and high viral load, it resulted in immune-suppression and suppression of red blood production in bone marrow. This is also consistent with the previous findings that predict the occurrence of TB which implied that advance disease condition in HIV patients may predict occurrence of Tuberculosis after ART initiation.</p><p>Different studies have shown that isoniazed (INH) preventive therapy reduces the risk of TB infection in people living with HIV <xref ref-type="bibr" rid="pone.0064488-Akolo1">[24]</xref>–<xref ref-type="bibr" rid="pone.0064488-Churchyard1">[27]</xref>. Similarly, in this study, patients who were on INH preventive therapy were at the lower risk of developing TB. The initiation of cotrimoxazole preventive therapy has also been independent predictor. TB/HIV collaborative actions should give priority high level of coverage to the implementation of these interventions as they have proven effectiveness in improving patients' conditions.</p><p>A Study from West Africa showed that ownership of the house by the TB patient's family associated with lower risk for TB <xref ref-type="bibr" rid="pone.0064488-Lienhardt1">[17]</xref>. But, this study didn't show statistical difference between those who had house and those who hadn't. This inconsistency might be due to source population difference, as the source population of this study was from the capital of the country.</p><p>This study has the following limitations: Case control study design could not set up temporal relationships and can only show associations; it could not proof causations. Recall bias might have also affected the accuracy of information related to substance use such as cigarette smoking and alcohol consumption. Lastly, challenges to diagnosis of tuberculosis in HIV patients might result in low sensitivity and specificity of available diagnostic approaches.</p></sec><sec id="s5"><title>Conclusion</title><p>Having poor clinical and biochemical status were found to be predicators of occurrence of Tuberculosis. All people living with HIV/AIDS should be screened for TB. But, in the presence of the risk factors mentioned in this paper, intensified screening is highly recommended during follow up of treatment. In addition, increasing coverage of INH and cotrimoxazole preventive therapy is necessary to reduce the overall risk of TB among HIV patients who started ART. Household condition related to kerosene use in household was also associated with outcome of interest.</p></sec></body><back><ack><p>The authors would like to thank all the staffs of Hospitals and Health centers, specially, in ART and TB clinic, and data collectors and study participants involved in the study.</p></ack><ref-list><title>References</title><ref id="pone.0064488-Preliminary1"><label>1</label><mixed-citation publication-type="other">Preliminary report for the U.S. Office of the Global AIDS Coordinator (2004) Integrating HIV/AIDS & TB Efforts. The Challenge for the President's AIDS Initiative. Network Public Health. February, 2004.</mixed-citation></ref><ref id="pone.0064488-Federal1"><label>2</label><mixed-citation publication-type="other">Federal Ministry of Health of Ethiopia (2007) Implementation Guideline for TB/HIV Collaborative Activities in Ethiopia. Addis Ababa: Ministry of Health. December 2007.</mixed-citation></ref><ref id="pone.0064488-World1"><label>3</label><mixed-citation publication-type="other">World Health Organization (2010) Global tuberculosis control: a short update to the 2012 report, Geneva. WHO 2010 (WHO/HTM/TB/2010.7).</mixed-citation></ref><ref id="pone.0064488-Global1"><label>4</label><mixed-citation publication-type="other">Global plan to stop TB 2011–2015 (2011) Transforming the fight to wards elimination of TB. (WHO/HTM/TB/2010.7) WHO, 2011.</mixed-citation></ref><ref id="pone.0064488-World2"><label>5</label><mixed-citation publication-type="other">World Health Organization (2011) Global tuberculosis control report. WHO 2011, Geneva</mixed-citation></ref><ref id="pone.0064488-World3"><label>6</label><mixed-citation publication-type="other">World Health Organization (2011) Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. WHO, Geneva, 2011.</mixed-citation></ref><ref id="pone.0064488-World4"><label>7</label><mixed-citation publication-type="other">World Health Organization (2012) Global tuberculosis control report. WHO, Geneva, 2012.</mixed-citation></ref><ref id="pone.0064488-World5"><label>8</label><mixed-citation publication-type="other">World Health Organization Global TB Report (2009) Available: <ext-link ext-link-type="uri" xlink:href="http://www.usaid.gov">www.usaid.gov</ext-link> Accessed 2012 Dec 12.</mixed-citation></ref><ref id="pone.0064488-Habib1"><label>9</label><mixed-citation publication-type="journal"><name><surname>Habib</surname><given-names>AG</given-names></name> (<year>2009</year>) <article-title>A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults</article-title>. <source>Annals of African Medicine</source><volume>8</volume><issue>3</issue>: <fpage>147</fpage>–<lpage>155</lpage><pub-id pub-id-type="pmid">19884690</pub-id></mixed-citation></ref><ref id="pone.0064488-Bonnet1"><label>10</label><mixed-citation publication-type="journal"><name><surname>Bonnet</surname><given-names>MMB</given-names></name>, <name><surname>Loretexu</surname><given-names>LPP</given-names></name>, <name><surname>Francis</surname><given-names>FVV</given-names></name>, <name><surname>Barbara</surname><given-names>BOO</given-names></name>, <name><surname>Daniel</surname><given-names>DOO'B</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden</article-title>. <source>AIDS</source><volume>20</volume><issue>9</issue>: <fpage>1275</fpage>–<lpage>1279</lpage><pub-id pub-id-type="pmid">16816556</pub-id></mixed-citation></ref><ref id="pone.0064488-Huruy1"><label>11</label><mixed-citation publication-type="journal"><name><surname>Huruy</surname><given-names>K</given-names></name>, <name><surname>Mulu</surname><given-names>A</given-names></name>, <name><surname>Mengstu</surname><given-names>G</given-names></name>, <name><surname>Shewa</surname><given-names>A</given-names></name>, <name><surname>Akalu</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Immune reconstitution inflammatory syndrome among HIV/AIDS patients during HAART in Addis Ababa,Ethiopia</article-title>. <source>Jpn J Infect. Dis</source><volume>61</volume>: <fpage>205</fpage>–<lpage>209</lpage><pub-id pub-id-type="pmid">18503170</pub-id></mixed-citation></ref><ref id="pone.0064488-Lawn1"><label>12</label><mixed-citation publication-type="journal"><name><surname>Lawn</surname><given-names>SD</given-names></name>, <name><surname>Badri</surname><given-names>M</given-names></name>, <name><surname>Wood</surname><given-names>R</given-names></name> (<year>2005</year>) <article-title>Tuberculosis among HIV infected patients receiving HAART: long term incidence and risk factors in a South African cohort</article-title>. <source>AIDS</source><volume>19</volume>: <fpage>2109</fpage>–<lpage>16</lpage><pub-id pub-id-type="pmid">16284460</pub-id></mixed-citation></ref><ref id="pone.0064488-Joshua1"><label>13</label><mixed-citation publication-type="journal"><name><surname>Joshua</surname><given-names>B</given-names></name>, <name><surname>Mayanja-Kizza</surname><given-names>H</given-names></name>, <name><surname>Moses</surname><given-names>RK</given-names></name>, <name><surname>John</surname><given-names>L</given-names></name>, <name><surname>Andrew</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Worsening and unmasking of tuberculosis in HIV-1infected patients after initiating highly active anti-retroviral therapy in Uganda</article-title>. <source>African Health Sci</source><volume>8</volume><issue>3</issue>: <fpage>190</fpage>–<lpage>195</lpage></mixed-citation></ref><ref id="pone.0064488-Boccia1"><label>14</label><mixed-citation publication-type="journal"><name><surname>Boccia</surname><given-names>D</given-names></name>, <name><surname>James</surname><given-names>H</given-names></name>, <name><surname>Bianca</surname><given-names>LDS</given-names></name>, <name><surname>Katherine</surname><given-names>F</given-names></name>, <name><surname>Chaap</surname><given-names>AbS</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>The Association between Household Socioeconomic Position and Prevalent Tuberculosis in Zambia: A Case-Control Study</article-title>. <source>PLoS ONE</source><volume>6</volume><issue>6</issue>: <fpage>e20824</fpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0020824">10.1371/journal.pone.0020824</ext-link></comment><pub-id pub-id-type="pmid">21698146</pub-id></mixed-citation></ref><ref id="pone.0064488-Joshua2"><label>15</label><mixed-citation publication-type="journal"><name><surname>Joshua</surname><given-names>Baalwa</given-names></name>, <name><surname>Mayanja-Kizza</surname><given-names>H</given-names></name>, <name><surname>Kamya</surname><given-names>MR</given-names></name>, <name><surname>John</surname><given-names>L</given-names></name>, <name><surname>Kambugu</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Worsening and unmasking of tuberculosis in HIV-1infected patients after initiating highly active anti-retroviral therapy in Uganda</article-title>. <source>African Health Sci</source><volume>8</volume><issue>3</issue>: <fpage>190</fpage>–<lpage>195</lpage></mixed-citation></ref><ref id="pone.0064488-Taha1"><label>16</label><mixed-citation publication-type="journal"><name><surname>Taha</surname><given-names>M</given-names></name>, <name><surname>Derbew</surname><given-names>A</given-names></name>, <name><surname>Tessema</surname><given-names>F</given-names></name>, <name><surname>Assegid</surname><given-names>S</given-names></name>, <name><surname>Duchateau</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Risk factors of active tuberculosis in people living with HIV/AIDS in southwest Ethiopia: a case control study</article-title>. <source>Ethiop J Health Sci</source><volume>21</volume><issue>2</issue>: <fpage>131</fpage>–<lpage>139</lpage><pub-id pub-id-type="pmid">22434992</pub-id></mixed-citation></ref><ref id="pone.0064488-Lienhardt1"><label>17</label><mixed-citation publication-type="journal"><name><surname>Lienhardt</surname><given-names>C</given-names></name>, <name><surname>Fielding</surname><given-names>K</given-names></name>, <name><surname>Sillah</surname><given-names>JS</given-names></name>, <name><surname>Bah</surname><given-names>B</given-names></name>, <name><surname>Gustafson</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa</article-title>. <source>Int J of Epidemiol</source><volume>34</volume>: <fpage>914</fpage>–<lpage>923</lpage><pub-id pub-id-type="pmid">15914505</pub-id></mixed-citation></ref><ref id="pone.0064488-HillPhilip1"><label>18</label><mixed-citation publication-type="journal"><name><surname>Hill Philip</surname><given-names>C</given-names></name>, <name><surname>Jackson-Sillah</surname><given-names>D</given-names></name>, <name><surname>Donkor</surname><given-names>SA</given-names></name>, <name><surname>Out</surname><given-names>J</given-names></name>, <name><surname>Adegbola</surname><given-names>RA</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Risk factors for pulmonary tuberculosis: a clinic-based case control study in The Gambia</article-title>. <source>BMC Public Health</source><volume>6</volume>: <fpage>156</fpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-6-156">10.1186/1471-2458-6-156</ext-link></comment><pub-id pub-id-type="pmid">16784521</pub-id></mixed-citation></ref><ref id="pone.0064488-Hermans1"><label>19</label><mixed-citation publication-type="journal"><name><surname>Hermans</surname><given-names>SM</given-names></name>, <name><surname>Kiragga</surname><given-names>A</given-names></name>, <name><surname>Schaefer</surname><given-names>P</given-names></name>, <name><surname>Kambugu</surname><given-names>A</given-names></name>, <name><surname>Hoepelman</surname><given-names>AIM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Incident Tuberculosis during Antiretroviral Therapy Contributes to Suboptimal Immune Reconstitution in a Large Urban HIV Clinic in Sub-Saharan Africa</article-title>. <source>PLoS ONE</source><volume>5</volume><issue>5</issue>: <fpage>e10527</fpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0010527">10.1371/journal.pone.0010527</ext-link></comment><pub-id pub-id-type="pmid">20479873</pub-id></mixed-citation></ref><ref id="pone.0064488-Rodwell1"><label>20</label><mixed-citation publication-type="journal"><name><surname>Rodwell</surname><given-names>L</given-names></name>, <name><surname>Richard</surname><given-names>FWB</given-names></name>, <name><surname>Moore</surname><given-names>M</given-names></name>, <name><surname>Strathdee</surname><given-names>SA</given-names></name>, <name><surname>Raich</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>HIV-Tuberculosis Coinfection in Southern California: Evaluating Disparities in Disease Burden</article-title>. <source>Am J Public Health</source><issue>Suppl 1</issue>: <fpage>S178</fpage>–<lpage>S185</lpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2105/AJPH.2009.170142">10.2105/AJPH.2009.170142</ext-link></comment><pub-id pub-id-type="pmid">20147681</pub-id></mixed-citation></ref><ref id="pone.0064488-Lnnroth1"><label>21</label><mixed-citation publication-type="journal"><name><surname>Lönnroth</surname><given-names>K</given-names></name>, <name><surname>Williams</surname><given-names>BG</given-names></name>, <name><surname>Stadlin</surname><given-names>S</given-names></name>, <name><surname>Jaramillo</surname><given-names>E</given-names></name>, <name><surname>Dye</surname><given-names>C</given-names></name> (<year>2008</year>) <article-title>Alcohol use as a risk factor for tuberculosis: a systematic review</article-title>. <source>BMC Public Health</source><volume>8</volume>: <fpage>289</fpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-8-289">10.1186/1471-2458-8-289</ext-link></comment><pub-id pub-id-type="pmid">18702821</pub-id></mixed-citation></ref><ref id="pone.0064488-Rehm1"><label>22</label><mixed-citation publication-type="journal"><name><surname>Rehm</surname><given-names>J</given-names></name>, <name><surname>Samokhvalov</surname><given-names>AV</given-names></name>, <name><surname>Neuman</surname><given-names>MG</given-names></name>, <name><surname>Room</surname><given-names>R</given-names></name>, <name><surname>Parry</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review</article-title>. <source>BMC Public Health</source><volume>9</volume>: <fpage>450</fpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-9-450">10.1186/1471-2458-9-450</ext-link></comment><pub-id pub-id-type="pmid">19961618</pub-id></mixed-citation></ref><ref id="pone.0064488-Komati1"><label>23</label><mixed-citation publication-type="journal"><name><surname>Komati</surname><given-names>S</given-names></name>, <name><surname>Shaw</surname><given-names>PA</given-names></name>, <name><surname>Stubbs</surname><given-names>N</given-names></name>, <name><surname>Mathibedi</surname><given-names>MJ</given-names></name>, <name><surname>Malan</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Tuberculosis Risk Factors and Mortality for HIV Infected Persons Receiving Antiretroviral Therapy in South Africa</article-title>. <source>AIDS</source><volume>24</volume><issue>12</issue>: <fpage>1849</fpage>–<lpage>1855</lpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e32833a2507">10.1097/QAD.0b013e32833a2507</ext-link></comment><pub-id pub-id-type="pmid">20622529</pub-id></mixed-citation></ref><ref id="pone.0064488-Akolo1"><label>24</label><mixed-citation publication-type="journal"><name><surname>Akolo</surname><given-names>C</given-names></name>, <name><surname>Adetifa</surname><given-names>I</given-names></name>, <name><surname>Shepperd</surname><given-names>S</given-names></name>, <name><surname>Volmink</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>Treatment of latent tuberculosis infection in HIV infected persons</article-title>. <source>Cochrane Database Syst Rev</source><issue>1</issue>: <fpage>CD000171</fpage><pub-id pub-id-type="pmid">20091503</pub-id></mixed-citation></ref><ref id="pone.0064488-Golub1"><label>25</label><mixed-citation publication-type="journal"><name><surname>Golub</surname><given-names>JE</given-names></name>, <name><surname>Saraceni</surname><given-names>V</given-names></name>, <name><surname>Cavalcante</surname><given-names>SC</given-names></name>, <name><surname>Pacheco</surname><given-names>AG</given-names></name>, <name><surname>Moulton</surname><given-names>LH</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil</article-title>. <source>AIDS</source><volume>21</volume><issue>11</issue>: <fpage>1441</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">17589190</pub-id></mixed-citation></ref><ref id="pone.0064488-Lawn2"><label>26</label><mixed-citation publication-type="journal"><name><surname>Lawn</surname><given-names>SD</given-names></name>, <name><surname>Wood</surname><given-names>R</given-names></name>, <name><surname>Cock</surname><given-names>KMD</given-names></name>, <name><surname>Kranzer</surname><given-names>K</given-names></name>, <name><surname>Lewi</surname><given-names>JJ</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Antiretroviral and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources</article-title>. <source>Lancet Infect Dis</source><volume>10</volume>: <fpage>489</fpage>–<lpage>98</lpage><pub-id pub-id-type="pmid">20610331</pub-id></mixed-citation></ref><ref id="pone.0064488-Churchyard1"><label>27</label><mixed-citation publication-type="journal"><name><surname>Churchyard</surname><given-names>GJ</given-names></name>, <name><surname>Fielding</surname><given-names>K</given-names></name>, <name><surname>Charalambous</surname><given-names>S</given-names></name>, <name><surname>Day</surname><given-names>JH</given-names></name>, <name><surname>Corbett</surname><given-names>EL</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Eficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?</article-title><source>AIDS</source><volume>17</volume>: <fpage>2063</fpage>–<lpage>2070</lpage><pub-id pub-id-type="pmid">14502009</pub-id></mixed-citation></ref><ref id="pone.0064488-Wolday1"><label>28</label><mixed-citation publication-type="journal"><name><surname>Wolday</surname><given-names>D</given-names></name>, <name><surname>Hailu</surname><given-names>B</given-names></name>, <name><surname>Girma</surname><given-names>M</given-names></name>, <name><surname>Hailu</surname><given-names>E</given-names></name>, <name><surname>Sanders</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Low CD4+ T-cell count and high HIV viral load precede the development oftuberculosis disease in a cohort of HIV-positive Ethiopians</article-title>. <source>Int J Tuberc Lung Dis</source><volume>7</volume><issue>2</issue>: <fpage>110</fpage>–<lpage>116</lpage><pub-id pub-id-type="pmid">12588010</pub-id></mixed-citation></ref><ref id="pone.0064488-Moore1"><label>29</label><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>D</given-names></name>, <name><surname>Liechty</surname><given-names>C</given-names></name>, <name><surname>Ekwarua</surname><given-names>P</given-names></name>, <name><surname>Werea</surname><given-names>W</given-names></name>, <name><surname>Mwimaa</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Prevalence, incidence and mortality associated with Tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda</article-title>. <source>AIDS</source><volume>21</volume><issue>6</issue>: <fpage>713</fpage>–<lpage>719</lpage><pub-id pub-id-type="pmid">17413692</pub-id></mixed-citation></ref><ref id="pone.0064488-Perez1"><label>30</label><mixed-citation publication-type="journal"><name><surname>Perez</surname><given-names>A</given-names></name>, <name><surname>Brown</surname><given-names>HS</given-names></name>, <name><surname>Restrepo</surname><given-names>BI</given-names></name> (<year>2006</year>) <article-title>Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas</article-title>. <source>Am J Trop Med Hyg</source><volume>74</volume><issue>4</issue>: <fpage>604</fpage>–<lpage>611</lpage><pub-id pub-id-type="pmid">16606993</pub-id></mixed-citation></ref><ref id="pone.0064488-Federal2"><label>31</label><mixed-citation publication-type="other">Federal Ministry of Health of Ethiopa (2008) Tuberculosis, Leprosy and TB/HIV prevention and control programme: Manual. Fourth ed. Addis Ababa, Ethiopia 2008.</mixed-citation></ref><ref id="pone.0064488-VanRie1"><label>32</label><mixed-citation publication-type="other">Van Rie A, Westerich D, Malope B, Badal-Faesen S, Rubel D, <etal>et al</etal>. (2007) Risk factors for incident pulmonary tuberculosis after the initiation of HAART in the Themba Lethu Clinical Cohort, Johannesburg, South Africa, 2007.</mixed-citation></ref><ref id="pone.0064488-Solomon1"><label>33</label><mixed-citation publication-type="other">Solomon T, Worku A (2011) The effect of HAART on incidence of tuberculosis among HIV infected patients in Hawassa University referral Hospital, South Ethiopia; a retrospective cohort study (unpublished).</mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002A34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3660598
|texte= Determinant Factors Associated with Occurrence of Tuberculosis among Adult People Living with HIV after Antiretroviral Treatment Initiation in Addis Ababa, Ethiopia: A Case Control Study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23762214" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |